Taysha Gene Therapies FY 2025 R&D expenses rise 30.91% to USD 86.4 million, net loss widens to USD 109 million

Reuters03-19
<a href="https://laohu8.com/S/TSHA">Taysha Gene Therapies</a> FY 2025 R&D expenses rise 30.91% to USD 86.4 million, net loss widens to USD 109 million
  • Taysha published a full-year earnings press release reporting revenue of USD 9.77 million and a net loss of USD 109 million, or USD 0.34 per share.
  • Research and development expenses rose 30.91% to USD 86.4 million, driven primarily by higher compensation from increased R&D headcount and higher clinical trial and GMP costs tied to REVEAL studies and BLA-enabling PPQ manufacturing initiatives.
  • General and administrative expenses increased 16.9% to USD 33.87 million, reflecting higher compensation, legal and professional fees, and debt issuance costs related to the 2025 Trinity term loan.
  • Cash and cash equivalents were USD 319.77 million, and the company said current cash resources are expected to fund planned operating expenses into 2028.
  • Multiple patients have been dosed in the REVEAL pivotal trial of TSHA-102, and management said it remains on track to complete dosing in the REVEAL pivotal and ASPIRE trials in Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190800PRIMZONEFULLFEED9675086) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment